NCT06721169 Phenol or Laser: Best Minimally Invasive Treatment for Pilonidal Sinus?
| NCT ID | NCT06721169 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Mersin University |
| Condition | Pilonidal Sinus Treatment |
| Study Type | OBSERVATIONAL |
| Enrollment | 64 participants |
| Start Date | 2024-12-28 |
| Primary Completion | 2026-10-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 64 participants in total. It began in 2024-12-28 with a primary completion date of 2026-10-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Pilonidal sinus disease is a common condition. There is still ongoing research on the ideal treatment. Pilonidal sinus disease is most common in men between the ages of 20 and 30. For patients with symptoms of pilonidal sinüs (pain, itching and discharge with soiling of underwear) that interfere with their normal daily life, several treatment options have emerged. A hairy body, thick skin, overweight, a deep gluteal cleft, lack of hygiene, sedentarism, repeated chafing and previous familial history are commonly admitted as predisposing factors. There are various surgical and non-surgical methods for its treatment. Many different surgical techniques have been defined. None of these surgical techniques are defined as 'gold standard'. For many years, wide excision and secondary healing was the standard approach for pilonidal sinus disease. However, when this method resulted in prolonged healing and restriction of regular activities, various reconstructive methods were developed to demonstrate the disadvantages of secondary healing. A minimally invasive treatment modality for pilonidal sinüs dissease is excision of the sinus pit(s) followed by application of phenol to the sinus tract. Phenol is a sclerosing agent that destroys the epithelium and debris in the sinus, and is, thus, able to promote healing of the sinus. Recently, advances in laser technology have made laser ablation of the sinus tract possible. The aim is to destroy and obliterate the sinus tracts with thermal energy produced by the laser probe. The aim of this prospective observational study was to compare phenolization and laser ablation in the treatment of pilonidal sinus disease.
Eligibility Criteria
Inclusion Criteria: * Patients aged 18 years and older with pilonidal sinus disease * Patients who have not had any previous treatment for pilonidal sinus disease * Patients with uncomplicated pilonidal sinus * Having been diagnosed with pilonidal sinus disease * Patients whose descriptive and clinical characteristics are recorded in their medical files * Those who have signed the Informed Voluntary Consent Form/Written Consent Form Exclusion Criteria: * Patients who have previously been treated for pilonidal sinus disease * Patients with complicated pilonidal sinus disease * Patients aged under 18 * Patients whose descriptive and clinical characteristics are not recorded in their file records * Those who have not signed the Informed Voluntary Consent Form/Written Consent Form
Contact & Investigator
Doğuş Parlak, PhD
STUDY DIRECTOR
Mersin University
Frequently Asked Questions
Who can join the NCT06721169 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Pilonidal Sinus Treatment. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06721169 currently recruiting?
Yes, NCT06721169 is actively recruiting participants. Contact the research team at hilmibozkurt27@gmail.com for enrollment information.
Where is the NCT06721169 trial being conducted?
This trial is being conducted at Mersin, Turkey (Türkiye).
Who is sponsoring the NCT06721169 clinical trial?
NCT06721169 is sponsored by Mersin University. The principal investigator is Doğuş Parlak, PhD at Mersin University. The trial plans to enroll 64 participants.